| Bioactivity | Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer[1][2][4]. |
| Invitro | Panitumumab (2 nM-2 μM, 3 h) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells[3].Panitumumab (0-200 μg/mL, 48 h) inhibits the proliferation of DLD-1 cells[4].Panitumumab (80 μg/mL, 24 h) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells[4]. Western Blot Analysis[3] Cell Line: |
| In Vivo | Panitumumab (25, 100, or 500 μg/mouse, i.p., twice a week) inhibits tumor growth in NCI-H1975 and NCI-H1650 xenografts, compared with control (P < 0.0003)[1]. Animal Model: |
| Name | Panitumumab |
| CAS | 339177-26-3 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yu Jo Chua, et al. Panitumumab. Drugs Today (Barc). 2006 Nov;42(11):711-9. [2]. Stefan Stremitzer, et al. Panitumumab safety for treating colorectal cancer. Expert Opin Drug Saf. 2014 Jun;13(6):843-51. [3]. Daniel J. Freeman, et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther (2009) 8 (6): 1536–1546. [4]. Efstathia Giannopoulou, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29(12):5077-82. |